Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 2/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 6/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.38 |
| ▸ | MAT2A | P31153 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 3/20 | 0.36 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27097293 | 0.88 | MAPK14 (0.35) | TLR9TLR7TLR8MAT2A | |
| SCHEMBL22906617 | 0.85 | TLR9 (0.42) | QDPRTLR9TLR7TLR8 | |
| SCHEMBL27097197 | 0.84 | QDPR (0.44) | QDPRTLR9TLR7TLR8MAT2A | |
| SCHEMBL27097204 | 0.79 | KHK (0.42) | — | |
| SCHEMBL27097206 | 0.74 | MAPT (0.39) | — | |
| SCHEMBL22906574 | 0.74 | ACHE (0.40) | — | |
| SCHEMBL27097281 | 0.72 | KHK (0.33) | — | |
| SCHEMBL22907358 | 0.72 | CHUK (0.36) | — | |
| SCHEMBL29773834 | 0.72 | CHUK (0.36) | — | |
| SCHEMBL27097190 | 0.71 | MAOA (0.35) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2021011913-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | QDPR 3556/4885TLR9 4826/4885TLR7 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.